A carregar...
EGFR inhibitor gefitinib prevents progression of pancreatic lesions to carcinoma in a conditional LSL-Kras(G12D/+) transgenic mice model
Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy with a dismal prognosis. Developing novel strategies to prevent/delay pancreatic cancer is currently of intense interest. The chemopreventive efficacy of gefitinib, an epidermal growth factor receptor (EGFR) inhibitor,...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3058550/ https://ncbi.nlm.nih.gov/pubmed/21084261 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1940-6207.CAPR-10-0038 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|